Publication: American Journal of Managed Care
Previously, patients with low expression of HER2 were categorized as HER2-negative, but adding the HER2-low classification creates new opportunities for patients with advanced breast cancer, explained Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology.
Click here to read the full article.